Synthesis and pharmacological evaluation of thiopyran analogues of the dopamine D3 receptor-selective agonist (4aR,10bR)-(+)-trans-3,4,4a,10b- tetrahydro-4-n-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol (PD 128907)

Journal of Medicinal Chemistry

Volumn 43, Issue 15, 2000, Pages 2871-2882

  Van Vliet, L Alexander ^a   Rodenhuis, Nienke ^a   Dijkstra, Durk ^a   Wikström, Håkan ^a   Pugsley, Thomas A ^b   Serpa, Kevin A ^b   Meltzer, Leonard T ^b   Heffner, Thomas G ^b   Wise, Lawrence D ^b   Lajiness, Mary E ^c   Huff, Rita M ^c   Svensson, Kjell ^c   Sundell, Staffan ^d   Lundmark, Max ^d  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b PFIZER INC   (United States)

^c CNS Diseases Research   (United States)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

3,4,4A,10B TETRAHYDRO 4 PROPYL 2H,5H [1]BENZOPYRANO[4,3 B][1,4]OXAZIN 9 OL; BENZOPYRAN DERIVATIVE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR STIMULATING AGENT; SEROTONIN 1A RECEPTOR; THIOPYRAN DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; DOPAMINE RELEASE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; ENANTIOMER; LOCOMOTION; NONHUMAN; RAT; REACTION ANALYSIS; RECEPTOR AFFINITY; STEREOCHEMISTRY;

ANIMALS; BENZOPYRANS; BINDING, COMPETITIVE; CHO CELLS; CORPUS STRIATUM; CRICETINAE; CRYSTALLOGRAPHY, X-RAY; CYCLIC S-OXIDES; DOPAMINE; DOPAMINE AGONISTS; MALE; MICRODIALYSIS; MORPHOLINES; MOTOR ACTIVITY; OXAZINES; RADIOLIGAND ASSAY; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN AGONISTS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0034721133     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0000113     Document Type: Article

References (56)

1. O'Dowd, B. F. Structures of dopamine receptors. J. Neurochem. 1993, 60, 804-816.
2. Ogawa, N. Molecular and chemical neuropharmacology of dopamine receptor subtypes. Acta Med. Okayama 1995, 49, 1-11.
3. Sokoloff, P.; Giros, B.; Martres, M. P.; Bouthenet, M. L.; Schwartz, J. C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990, 347, 146-151.
4. Levesque, D.; Diaz, J.; Pilon, C.; Martres, M. P.; Giros, B.; Souil, E.; Schott, D.; Morgat, J. L.; Schwartz, J. C.; Sokoloff, P. Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N,N-di-n-propyl-2-aminotetralin. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 8155-8159.
5. Hall, H.; Halldin, C.; Dijkstra, D.; Wikström, H.; Wise, L. D.; Pugsley, T. A.; Sokoloff, P.; Pauli, S.; Farde, L.; Sedvall, G. Autoradiographic localisation of D3-dopamine receptors in the human brain using the selective D3-dopamine receptor agonist (+)-[3H]PD 128907. Psychopharmacology (Berlin) 1996, 128, 240-247.
6. Van Tol, H. H.; Bunzow, J. R.; Guan, H. C.; Sunahara, R. K.; Seeman, P.; Niznik, H. B.; Civelli, O. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991, 350, 610-614.
7. Levant, B. The D3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacol. Rev. 1997, 49, 231-252.
8. Joyce, J. N.; Gurevich, E. V. Dopamine D3 receptors: from anatomy to neuropsychiatry. Neurosci. News 1999, 2, 11-21.
9. Svensson, K.; Carlsson, A.; Waters, N. Locomotor inhibition by the D3 ligand R-(+)-7-OH-DPAT is independent of changes in dopamine release. J. Neural Transm. Gen. Sect. 1994, 95, 71-74.
10. Waters, N.; Svensson, K.; Haadsma Svensson, S. R.; Smith, M. W.; Carlsson, A. The dopamine D3-receptor: a postsynaptic receptor inhibitory on rat locomotor activity [see comments]. J. Neural Transm. Gen. Sect. 1993, 94, 11-19.
11. Meller, E.; Bohmaker, K.; Goldstein, M.; Basham, D. A. Evidence that striatal synthesis-inhibiting autoreceptors are dopamine D3 receptors. Eur. J. Pharmacol. 1993, 249, R5-R6.
12. Caine, S. B.; Koob, G. F. Modulation of cocaine self-administration in the rat through D-3 dopamine receptors. Science 1993, 260, 1814-1816.
13. Acri, J. B.; Carter, S. R.; Ailing, K.; Geter Douglass, B.; Dijkstra, D.; Wikström, H.; Katz, J. L.; Witkin, J. M. Assessment of cocaine-like discriminative stimulus effects of dopamine D3 receptor ligands. Eur. J. Pharmacol. 1995, 281, R7-R9.
14. Millan, M. J.; Peglion, J. L.; Vian, J.; Rivet, J. M.; Brocco, M.; Gobert, A.; Newman Tancredi, A.; Dacquet, C.; Bervoets, K.; Girardon, S.; Jacques, V.; Chaput, C.; Audinot, V. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy. J. Pharmacol. Exp. Ther. 1995, 275, 885-898.
15. 3 Receptor Agonist, R(+)-7-Hydroxy-N,N-di-n-propyl-2-aminotetralin, on Memory Processes in Mice. Eur. J. Pharmacol. 1997, 324, 147-151.
16. Svensson, K.; Johansson, A. M.; Magnusson, T.; Carlsson, A. (+)-AJ 76 and (+)-UH 232: central stimulants acting as preferential dopamine autoreceptor antagonists. Naunyn-Schmiedeberg's Arch. Pharmacol. 1986, 334, 234-245.
17. Johansson, A. M.; Arvidsson, L. E.; Hacksell, U.; Nilsson, J. L.; Svensson, K.; Hjorth, S.; Clark, D.; Carlsson, A.; Sanchez, D.; Andersson, B.; et al. Novel dopamine receptor agonists and antagonists with preferential action on autoreceptors. J. Med. Chem. 1985, 28, 1049-1053.
18. Millan, M. J.; Audinot, V.; Rivet, J. M.; Gobert, A.; Vian, J.; Prost, J. F.; Spedding, M.; Peglion, J. L. S 14297, a novel selective ligand at cloned human dopamine D3 receptors, blocks 7-OH-DPAT-induced hypothermia in rats. Eur. J. Pharmacol. 1994, 260, R3-R5.
19. Sautel, F.; Griffon, N.; Sokoloff, P.; Schwartz, J. C.; Launay, C.; Simon, P.; Costentin, J.; Schoenfelder, A.; Garrido, F.; Mann, A. Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents. J. Pharmacol. Exp Ther. 1995, 275, 1239-1246.
20. 3 Antagonist. Pharmacol. Biochem. Behav. 1997, 59, 487-493.
21. Damsma, G.; Bottema, T.; Westerink, B. H.; Tepper, P. G.; Dijkstra, D.; Pugsley, T. A.; MacKenzie, R. G.; Heffner, T. G.; Wikström, H. Pharmacological aspects of R-(+)-7-OH-DPAT, a putative dopamine D3 receptor ligand. Eur. J. Pharmacol. 1993, 249, R9-R10.
22. van Vliet, L. A.; Tepper, P. G.; Dijkstra, D.; Damsma, G.; Wikström, H.; Pugsley, T. A.; Akunne, H. C.; Heffner, T. G.; Glase, S. A.; Wise, L. D. Affinity for dopamine D2, D3, and D4 receptors of 2-aminotetralins. Relevance of D2 agonist binding for determination of receptor subtype selectivity. J. Med. Chem. 1996, 39, 4233-4237.
23. Baldessarini, R. J.; Kula, N. S.; McGrath, C. R.; Bakthavachalam, V.; Kebabian, J. W.; Neumeyer, J. L. Isomeric selectivity at dopamine D3 receptors. Eur. J. Pharmacol. 1993, 239, 269-270.
24. Cannon, J. G.; Hatheway, G. J. Centrally acting emetics. 10. Rigid dopamine congeners derived from octahydrobenzo[f]quinoline. J. Med. Chem. 1976, 19, 987-993.
25. Cannon, J. G.; Suarez Gutierrez, C.; Lee, T.; Long, J. P.; Costall, B.; Fortune, D. H.; Naylor, R. J. Rigid congeners of dopamine based on octahydrobenzo[f]quinoline: peripheral and central effects. J. Med. Chem. 1979, 22, 341-347.
26. Cannon, J. G.; Lee, T.; Goldman, H. D.; Long, J. P.; Flynn, J. R.; Verimer, T.; Costall, B.; Naylor, R. J. Congeners of the beta conformer of dopamine derived from cis- and trans-octahydrobenzo[f]quinoline and trans-octahydrobenzo[g]quinoline. J. Med. Chem. 1980, 23, 1-5.
27. Bach, N. J.; Kornfeld, E. C.; Clemens, J. A.; Smalstig, E. B. Conversion of ergolines to hexahydro- and octahydrobenzo[f]-quinolines (depyrroloergolines). J. Med. Chem. 1980, 23, 812-814.
28. Wikström, H.; Sanchez, D.; Lindberg, P.; Arvidsson, L. E.; Hacksell, U.; Johansson, A.; Nilsson, J. L.; Hjorth, S.; Carlsson, A. Monophenolic octahydrobenzo[f]quinolines: central dopamine- and serotonin-receptor stimulating activity. J. Med. Chem. 1982, 25, 925-931.
29. Craig, J. C.; Torkelson, S. M.; Findell, P. R.; Weiner, R. I. Synthesis and dopaminergic activity of 2-substituted octahydrobenzo[f]quinolines. J. Med. Chem. 1989, 32, 961-968.
30. Wikström, H.; Andersson, B.; Sanchez, D.; Lindberg, P.; Arvidsson, L. E.; Johansson, A. M.; Nilsson, J. L.; Svensson, K.; Hjorth, S.; Carlsson, A. Resolved monophenolic 2-aminotetralins and 1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolines: structural and stereochemical considerations for centrally acting pre- and postsynaptic dopamine-receptor agonists. J. Med. Chem. 1985, 28, 215-225.
31. Jones, J. H.; Anderson, P. S.; Baldwin, J. J.; Clineschmidt, B. V.; McClure, D. E.; Lundell, G. F.; Randall, W. C.; Martin, G. E.; Williams, M.; Hirshfield, J. M.; Smith, G.; Lumma, P. K. Synthesis of 4-substituted 2H-naphth[1,2-b]-1,4-oxazines, a new class of dopamine agonists. J. Med. Chem. 1984, 27, 1607-1613.
32. Dijkstra, D.; Hazelhoff, B.; Mulder, T. B. A.; de Vries, J. B.; Wynberg, H.; Horn, A. S. Synthesis and Pharmacological Activity of the Hexahydro-4H-naphth[1,2b][1,4]-oxazines: a New Series of Potent Dopamine Receptor Agonists. Eur. J. Med. Chem. 1985, 20, 247-250.
33. a values for central dopamine receptor activation. J. Med. Chem. 1988, 31, 2178-2182.
34. DeWald, H. A.; Heffner, T. G.; Jaen, J. C.; Lustgarten, D. M.; McPhail, A. T.; Meltzer, L. T.; Pugsley, T. A.; Wise, L. D. Synthesis and dopamine agonist properties of (+-)-trans-3,4,-4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano [4,3-b]-1,4-oxazin-9-ol and its enantiomers. J. Med. Chem. 1990, 33, 445-450.
35. Pugsley, T. A.; Davis, M. D.; Akunne, H. C.; MacKenzie, R. G.; Shih, Y. H.; Damsma, G.; Wikström, H.; Whetzel, S. Z.; Georgic, L. M.; Cooke, L. W.; Demattos, S. B.; Corbin, A. E.; Glase, S. A.; Wise, L. D.; Dijkstra, D.; Heffner, T. G. Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907. J. Pharmacol. Exp. Ther. 1995, 275, 1355-1366.
36. Akunne, H. C.; Towers, P.; Ellis, G. J.; Dijkstra, D.; Wikström, H.; Heffner, T. G.; Wise, L. D.; Pugsley, T. A. Characterization of binding of [3H]PD 128907, a selective dopamine D3 receptor agonist ligand, to CHO-K1 cells. Life Sci. 1995, 57, 1401-1410.
37. Burger, A. Isosterism and bioisosterism in drug design. Prog. Drug Res. 1991, 37, 287-371.
38. Patani, G. A.; LaVoie, E. J. Bioisosterism: A Rational Approach in Drug Design. Chem. Rev. 1996, 96, 3147-3176.
39. Davis, A. M.; Teague, S. J. Hydrogen Bonding, Hydrophobic Interactions, and Failure of the Rigid Receptor Hypothesis. Angew. Chem., Int. Ed. Engl. 1999, 38, 736-749.
40. Pallas version 1.2 is commercially available software from CompuDrug Chemistry Ltd.. 1994.
41. Kessler, R. M.; Ansari, M. S.; de Paulis, T.; Schmidt, D. E.; Clanton, J. A.; Smith, H. E.; Manning, R. G.; Gillespie, D.; Ebert, M. H. High affinity dopamine D2 receptor radioligands. 1. Regional rat brain distribution of iodinated benzamides. J. Nucl. Med. 1991, 32, 1593-1600.
42. Huntress, E. H.; Carten, F. H. Identification of Organic Compounds. I. Chlorosulfonic Acid as a Reagent for the Identification of Aryl Halides. J. Am. Chem. Soc. 1940, 62, 511-514.
43. Adams, R.; Marvel, C. S. Thiophenol. Organic Syntheses; John Wiley & Sons: New York, 1941; Coll. Vol. I, pp 504-506.
44. Adams, R.; Marvel, C. S. Thiophenol. Organic Syntheses; John Wiley & Sons: New York, 1941; Coll. Vol. I, pp 504-506.
45. Arndt, F.; Flemming, W.; Scholz, E.; Löwensohn, V. Thioflavanone, Thio-chromanone und -chromonole. Ber. 1923, 56, 1269-1279.
46. Furniss, B. S.; Hannaford, A. J.; Smith, P. W. G.; Tatchell, A. R. a-Tetralone. Vogel's Textbook of Practical Organic Chemistry; Longman Scientific & Technical: Harlow, Essex, England, 1989; p 1016.
47. Melillo, D. G.; Larsen, R. D.; Mathre, D. J.; Shukis, W. F.; Wood, A. W.; Colleluori, J. R. Practical Enantioselective Synthesis of a Homotyrosine Derivative and (R,R)-4-Propyl-9-hydroxynaphthoxazine, a Potent Dopamine Agonist. J. Org. Chem. 1987, 52, 5143-5150.
48. Lajiness, M. E.; Chio, C. L.; Huff, R. M. D2 dopamine receptor stimulation of mitogenesis in transfected Chinese hamster ovary cells: relationship to dopamine stimulation of tyrosine phosphorylations. J. Pharmacol. Exp. Ther. 1993, 267, 1573-1581.
49. Chio, C. L.; Lajiness, M. E.; Huff, R. M. Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors. Mol. Pharmacol. 1994, 45, 51-60.
50. Kurashima, M.; Yamada, K.; Nagashima, M.; Shirakawa, K.; Furukawa, T. Effects of putative dopamine D3 receptor agonists, 7-OH-DPAT, and quinpirole, on yawning, stereotypy, and body temperature in rats. Pharmacol. Biochem. Behav. 1995, 52, 503-508.
51. Ungerstedt, U. Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand. Suppl. 1971, 367, 69-93.
52. Ungerstedt, U.; Arbuthnott, G. W. Quantitative recording of rotational behavior in rats after 6-hydroxy-doparaine lesions of the nigrostriatal dopamine system. Brain Res. 1970, 24, 485-493.
53. Sanderson, R. T. Electronegativity and Bond Energy. J. Am. Chem. Soc. 1983, 105, 2259-2261.
54. Argiolas, A.; Melis, M. R. The Neuropharmacology of Yawning. Eur. J. Pharmacol. 1998, 343, 1-16.
55. Bristow, L. J.; Cook, G. P.; Gay, J. C.; Kulagowski, J. J.; Landon, L.; Murray, F.; Saywell, K. L.; Young, L.; Hutson, P. H. The behavioural and neurochemical profile of the putative dopamine D3 receptor agonist, (+)-PD 128907, in the rat. Neuropharmacology 1996, 35, 285-294.
56. Westerink, B. H. C. Monitoring Molecules in the Conscious Brain by Microdialysis. Trends Anal. Chem. 1992, 11, 176-182.